Is Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Mirum Pharmaceuticals, Inc. at current levels.
Rare-disease cash machine with three Phase 3 readouts that could transform a one-drug story into a four-drug franchise.
Where MIRM is headed
Mirum walks into 2028 as a profitable rare-disease company doing north of $750M in revenue, with LIVMARLI as the global standard of care across three cholestatic indications and a second commercial pillar emerging from volixibat. The Alagille and PFIC label expansions in Europe and Japan are largely complete, biliary atresia data has either cracked open a $1B+ pediatric liver opportunity or quietly closed that door, and the Travere-acquired Chenodal franchise for cerebrotendinous xanthomatosis (CTX) is delivering high-margin US revenue that the market currently ignores.
Read the full Compass Direction on MIRM
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $96.95).
See the full MIRM analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Mirum Pharmaceuticals, Inc. at current levels. Rare-disease cash machine with three Phase 3 readouts that could transform a one-drug story into a four-drug franchise.
What is MIRM's Compass Score?
Mirum Pharmaceuticals, Inc. scores 75/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for MIRM?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the MIRM page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.